Article
Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.
The Journal of clinical investigation - 1 May 1993
Evans W E, Relling M V, Rahman A, McLeod H L, Scott E P, Lin J S
Abstract excerpt
Debrisoquin hydroxylase (CYP2D6) is a cytochrome P450 enzyme that catalyzes the metabolism of > 30 commonly prescribed medications. Deficiency in CYP2D6 activity, inherited as an autosomal recessive trait, was found to be significantly less common in American blacks (1.9%) than whites (7.7%). To determine the genetic basis for this difference, inactivating CYP2D6 mutations were assessed by allele-specific PCR...
Topics
- Base Sequence
- Black People
- Cytochrome P-450 CYP2D6
- Cytochrome P-450 Enzyme System
- DNA
- Gene Deletion
- Genotype
- Humans
- Leukocytes
- Mixed Function Oxygenases
- Molecular Sequence Data